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To determine the optimum duration of follow-up for the assessment of drug efﬁcacy against Plasmodium
falciparum malaria, 96 trial arms from randomized controlled trials (RCTs) with follow-up of 28 days or longer
that were conducted between 1990 and 2003 were analyzed. These trials enrolled 13,772 patients, and partic-
ipating patients comprised 23% of all patients enrolled in RCTs over the past 40 years; 61 (64%) trial arms
were conducted in areas where the rate of malaria transmission was low, and 58 (50%) trial arms were
supported by parasite genotyping to distinguish true recrudescences from reinfections. The median overall
failure rate reported was 10% (range, 0 to 47%). The widely used day 14 assessment had a sensitivity of between
0 and 37% in identifying treatment failures and had no predictive value. Assessment at day 28 had a sensitivity
of 66% overall (28 to 100% in individual trials) but could be used to predict the true failure rate if either
parasite genotyping was performed (r
2  0.94) or if the entomological inoculation rate was known. In the
assessment of drug efﬁcacy against falciparum malaria, 28 days should be the minimum period of follow-up.
Clinical trials of antimalarial drugs have been conducted for
over 100 years (7, 71). The number of trials and their size have
increased markedly in recent years; half of all published ran-
domized trials have been conducted in the past 7 years, and the
average number of patients included in trials has tripled (34).
The design of trials testing the efﬁcacy of drugs against Plas-
modium falciparum malaria was ﬁrst standardized by the
World Health (WHO) between 1965 and 1973. To assess the
efﬁcacy of the 4-aminoquinolines (chloroquine and amodia-
quine), a 28-day period of follow-up was proposed and gener-
ally adopted (70). During the introduction of meﬂoquine
(which has a terminal elimination half-life of approximately 2
weeks in cases of malaria) it was observed that some recrudes-
cences can occur after this 28-day period, and so longer fol-
low-up periods were employed during some of the initial eval-
uations of this drug (16). In recent years, particularly following
a review and report in 1996 by the WHO, a shorter period of
follow-up (14 days) was suggested for the evaluation of anti-
malarial drugs in settings where the rate of malaria transmis-
sion was high (72). This has been used widely both in low- and
high-transmission settings. Thus, in recent years there has been
an increase both in the number of clinical trials with a short
period of follow-up and also in periods of follow-up longer
than 28 days, in southeast Asia, where meﬂoquine and other
new antimalarials have been evaluated (14, 17, 34, 36, 53,
61–64).
In the past, accurate assessments of the efﬁcacy of drugs
against P. falciparum malaria required that the patient should
not be exposed again to malarial infection during the follow-up
period, as recrudescence and reinfection could not be distin-
guished reliably on clinical or parasitological grounds. This
limited the conduct of trials to areas where the disease was not
endemic or to in-hospital facilities. The introduction of molec-
ular genotyping methods has allowed recrudescent infections
to be distinguished reliably from newly acquired infections,
and thus trials can now be conducted in areas where the dis-
ease is endemic—even those areas where the rate of malaria
transmission is high (4, 13). This has allowed large community-
based trials with extended follow-up to be conducted in ma-
laria-affected communities and led to a recent considerable
increase in both the number and size of antimalarial drug
studies. It is increasingly accepted that cure of malaria infec-
tion should be the objective of treatment, as treatment failure
(i.e., recrudescence) is associated with increased morbidity
even in areas where transmission is high and reinfection is
inevitable (37). Recrudescences encourage the spread of resis-
tance. As resistance worsens, treatment failures manifest pro-
gressively earlier than after initial treatment (69), until para-
sitemia is no longer cleared (WHO resistance level R2) and
then no longer responds at all to the antimalarial drug (WHO
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4271resistance level R3). As a consequence, mortality rises. Critical
to the accurate deﬁnition of drug-resistant malaria is the length
of follow-up. Various times have been adopted, ranging from 7
to 63 days, but 14 and 28 days are the durations used most
commonly. We present a review of antimalarial drug trials that
we have conducted since 1990 with follow-up periods of 28
days or longer to assess the optimum duration of observation
for the accurate characterization of antimalarial drug efﬁcacy
in vivo.
MATERIALS AND METHODS
Data were obtained retrospectively from antimalarial drug trials in uncompli-
cated falciparum malaria that have been conducted or coordinated where indi-
vidual patient follow-up was carried out for at least 28 days. We particularly
sought those trials that were randomized and in which recrudescence could be
reliably distinguished from new infection by PCR genotyping (i.e., true treatment
failure rates were known). In the majority of studies, genotyping involved com-
parison by PCR of variable blocks within merozoite surface protein 1 (MSP1),
merozoite surface protein 2 (MSP2), and glutamate-rich protein (GLURP) (7,
13). The objectives of this study were (i) to deﬁne a reference (true) parasito-
logical failure rate, (ii) to compare the day 14 and day 28 failure rates with this
true failure rate to establish the usefulness of either in predicting true failure,
and (iii) to compare the widely used day 14 to the day 28 failure rates. The
sources of the trials analyzed are given in Table 1.
Deﬁnition of endpoints. The unit of analysis was an arm in a antimalarial drug
trial. For those studies with 63 days of follow-up, we considered the day 63,
PCR-adjusted treatment failure rate as the reference or the true failure rate,
because recrudescence in a nonpregnant patient after this time is very unlikely
(52).
We deﬁned early failures as cases where parasitemia had not fallen by more
than 75% at 48 h after starting treatment (original WHO classiﬁcation, R3) (70).
Where a precise 48-h value was not available, the day 3 value was used instead.
Failures at any later time were deﬁned by positive (i.e., detectable on blood
smear) parasitemia. The numbers of failures at 7, 14, 28, 42, and 63 days were
compared. Patients who deteriorated clinically between days 2 and 7 with per-
sistent or rising parasitemia were pooled with the day 7 failures.
In each trial, at each time point, we documented the number of patients
examined and the number of failures that had occurred. We documented the
number of samples that were PCR genotyped, the number of those classiﬁed as
recrudescent infections, and the number of samples which could not be classiﬁed
reliably in the PCR analysis (i.e., were considered indeterminate). Failures be-
fore or on day 7 (i.e., without parasite clearance) were not genotyped, as they
were assumed to have derived only from the initial symptomatic infection. The
PCR results were used to estimate the number of true failures in each individual
trial after day 7 with the following formula: estimated number of true treatment
failures after day 7  number of patients with recurrent parasitemia  [(number
of recrudescences by PCR)/(number of samples for which PCR analysis was done
 number of indeterminate samples)].
A number of explanatory variables characterizing each trial arm were also
recorded. These were country where the study was conducted, estimated con-
temporaneous entomological inoculation rate (EIR), year when the study
started, the drugs used and their total doses, total number of patients, mean or
median age of the patients, standard deviation of age, range of age, geometric
mean parasitemia at day 0, range of parasitemias at day 0, the mean or median
parasite clearance time, and mean or median fever clearance time. The study
areas were divided arbitrarily into low-transmission (estimated EIR, 2 infec-
tious bites/person/year), medium-transmission (estimated EIR, 2 to 10 infectious
bites/person/year), and high-transmission (estimated EIR, 10 infectious bites/
person/year) settings.
Data from the published literature. We also reviewed all randomized con-
trolled trials published in the past 40 years in which parasitological failure rates
at both day 14 and day 28 or later were quoted (34), excluding those published
trials which were included in this more-detailed evaluation.
Statistical analysis of failure rates. Data were analyzed with STATA, version
8.0 (Stata Corp., College Station, Tex.).
Data were provided as count data, i.e., the number of observed patients for
each time interval and the number of patients with treatment failures, and then
transformed into survival time data. Patients lost to follow-up were treated as
censored at the last examination. Patients who missed an examination at time t
but were still parasite negative when they returned at time t  1 examination
were assumed to have been negative at time t. The estimated numbers of true
failures were rounded to the nearest integer. New infections or samples inde-
terminate by PCR were treated as censored.
The trials differed in design. In several trials, where PCR genotyping was
performed, it was not conducted on every treatment failure. The detailed anal-
yses were therefore done only of data from trials in which PCR results were
available at least for failures occurring at 14 days and also at 28 days follow-
ing the start of treatment. The numbers of trials and corresponding numbers of
patients for the different periods of follow-up are shown in Fig. 1. Cumulative
failure rates were estimated individually by the Kaplan-Meier method for each
trial arm. The cumulative failure rate estimates at days 14, 28, and 63 were
compared within trial arms. The relationship between the day 63 failure rate and
failure rate estimates at day 14 or day 28 was examined by linear regression,
which also explored associations with the individual trial characteristics.
The longer a patient is followed, the more likely a new malaria infection is to
occur. This cumulative probability distribution is determined by the malaria
transmission intensity. We modeled the relationship between the cumulative
proportion of true failures detected in these studies and the duration of fol-
low-up with a three-parameter logistic function
y  b1/1  e
b2x  b3	 (1)
where b1, b2, and b3 are the parameters, x is duration of follow-up, and y is the
cumulative proportion of true failures detected.
The relationship between the proportion of all recurrent parasitemias that
were recrudescences and the true failure rate was modeled using the negative
exponential growth function
y  b1/1  e
b2x	 (2)
where b1 and b2 are parameters, x is the true failure rate, and y is the proportion
of all recurrent parasitemias which were recrudecences.
TABLE 1. Sources of trials included in this study
Organization and
location(s) of trial
No. of
trial arms
Reference(s)
or source
Shoklo Malaria Research Unit,
Mae Sot, Tak, Thailand
50 22–24, 29–33, 35, 36,
41–44, 54, 57, 58, 61–64
F. Nosten, unpublished
data
Epicentre, Paris, France 9
Uganda 5 21
Laos 1 15
Liberia 3 5, 6
J. P. Guthmann, unpub-
lished data
South East African Combination
Antimalarial Therapy
4 K. Barnes, unpublished
data
Mozambique 1
South Africa 3
Vietnam 6 17
T. T. Hien, unpublished
data
Laos 4 27, 28
Thailand 7 48, 49, 60
Medecins sans Frontie `res-
Holland, Yangon, Myanmar
10 53, 54
F. Smithuis, unpublished
data
Tropical Diseases Research,
WHO, Geneva, Switzerland
26
Peru 2 2
Sa ˜o Tome ´2 2
Senegal 2 1
Uganda 3 2
Kenya 5 1, 2
Malawi 3 2
Burkina Faso 2 2
Co ˆte d’Ivoire 2 2
Gabon 2 1
The Gambia 3 66
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Data were obtained from 116 antimalarial drug trial arms
which had enrolled 16,281 patients and which were carried out
between 1990 and 2003 (Table 1). Of these, 96 trial arms
(13,772 patients; 85% of all patients) came from randomized
controlled trials (Fig. 1). This comprises 23% of all patients
enrolled in published randomized trials in uncomplicated ma-
laria caused by P. falciparum over the past 40 years (34).
Table 2 summarizes the trials’ characteristics. Overall, 67%
of studies (treatment arms) were located in Asia; 90% of stud-
ies were carried out on at least 60 patients, while 20% had 200
or more patients enrolled. More than half, or 73 of the studies
(63%; 9,959 patients) of the trials were conducted in areas of
where the rate of transmission of malaria was low, and only 14
(12%; 2,255 patients) trials came from stable high-transmission
areas. Studies from high-transmission areas were never longer
than 28 days. All 17 studies with 63 days of follow-up came
from low-transmission areas. Overall, 21 studies (19%) were
carried out with children only (
15 years of age), and 20
studies (17%) included only adults (14 years of age).
Patients were treated with a wide selection of drug regimens:
(i) artesunate or artemether alone or in combination with
antibiotics (clindamycin and doxycycline), (ii) chloroquine
alone or in combination with artesunate or quinine, (iii) halo-
fantrine, (iv) artemether-lumefantrine, (v) meﬂoquine alone or
in combination with artesunate or artemether, (vi) quinine
alone or in combination with antibiotics (clindamycin, ri-
fampin, tetracycline, and doxycycline), (vii) sulfadoxine-pyri-
methamine alone or in combination with artesunate, (viii) di-
hydroartemisinin-piperaquine, or (ix) atovaquone-proguanil
alone or in combination with artesunate.
As slowly eliminated antimalarial drugs suppress reinfections
and delay the appearance of recrudescences (69), the treatments
were grouped into three categories according to the antimala-
rial drug terminal elimination half-life or, in case of combina-
tion treatment, according to the longest half-life of the compo-
nent drugs (Table 3). Overall, 29% of trials used drugs with
short half-lives (
1 day), 18% used drugs with medium half-lives
(1 to 7 days), and 53% used drugs with long half-lives (7 days).
FIG. 1. Summary of trial arms and patient numbers.
TABLE 2. Characteristics of trials included in the study
Characteristic
a No. (%) of
treatment arms
Median
(range)
No. of patients 116 129 (18–533)
Continent
Africa 36 (31)
Asia 78 (67)
South America 2 (2)
Estimated entomological inocu-
lation rate (no. of infectious
bites/person/year)
Low (
2) 73 (63)
Medium (2–10) 29 (25)
High (10) 14 (12)
Drug terminal elimination
half-life (days)
Short (
1) 21 (18)
Medium (1–7) 38 (33)
Long (7) 57 (49)
Mean age (yr) 116 18 (1.3–33)
Geometric mean parasitemia
at admission/l
114 10,070 (670–347,400)
Mean FCT (h) 84 31 (19–62)
Mean PCT (h) 85 62 (24–228)
a FCT, fever clearance time; PCT, parasite clearance time.
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was performed on data from 64 trial arms, 54 of which had
PCR results for failures occurring at or before day 14 and at or
before day 28. In addition, four trial arms had no failures
observed during the 28-day follow-up period. Thus, accurate
assessments for up to 28 days after the start of the treatment
were available for 58 trial arms. Among these 58 trial arms,
data from 26 trial arms had also PCR genotyping done for any
failures occurring before day 42 of follow-up, and 17 arms had
PCR results for failures occurring at any time up to 63 days
follow-up. For failures occurring before day 14, the true failure
rate was the same as the PCR-corrected value in 22 of 30 trials
(73%) (i.e., all of the observed failures were true recrudes-
cences), while this proportion decreased for assessments at
later times, in 32 of 51 (day 28), 6 of 20 (day 42), and 3 of 11
(day 63) trials.
(i) Studies with 63-day follow-up (17 trial arms). The day 14
assessment missed between 64 and 100% of all treatment fail-
ures in these studies (i.e., sensitivity was from 0 to 36%). The
day 28 assessment missed between 8 and 84% (median, 40%)
of failures, with the higher values coming from trials of slowly
eliminated drugs with low levels of resistance (i.e., trials with
few failures). Pooling all the results between the studies, the
day 14 assessment missed 177 of 196 true failures (90%; overall
sensitivity, 10%), and the day 28 assessment missed 67 of 196
failures (34%, overall sensitivity, 66%). As can be seen in Fig.
2, the day 14 assessment missed all failures following treatment
with rapidly eliminated drugs in these studies.
(ii) Studies with 42-day follow-up (26 trial arms). Compared
with the day 42 assessment results, a median of 86% of failures
were missed by day 14 assessment (range, 20 to 100%), and
18% (range, 0 to 100%) were missed by the day 28 assessment.
When results from all 26 study arms with day 42 assessments
were pooled, it was found that the day 14 assessment missed
159 (75%; overall sensitivity, 25%), and the day 28 assessment
missed 32 (15%; overall sensitivity, 85%) of the 212 failures
detected. When the overall failure rate was 
10% (15 studies),
the day 28 median underassessment was 26% (range, 0 to
100%), and when the failure rate exceeded 10% (11 studies),
the day 28 assessment missed 15% (range, 0 to 40%).
(iii) Studies with 28-day follow-up (58 trial arms). Observed
failure rates at day 28 were nearly always much higher than
rates at day 14. Of those trials with PCR-corrected results, 50%
had failure rates at day 28 that were at least 2.6 times higher
than the corresponding rate at day 14 (range, 1 to 22 times).
The day 14 median underassessment of failure rate assessed at
day 28 was 71%. In 50% of trials, more than 70% of failures
occurred between days 14 and 28 (range, 0 to 100%). In the
four trial arms with rapidly eliminated drugs, none of the
failures was detected at day 14. A median of 9% of failures
were detected at day 14 in trials with drugs with half-lives of 1
to 7 days (23 studies), and median of 34% of failures were
detected in trials with slowly eliminated drugs (25 studies).
Figure 3 shows scatter plots of failure rates at days 14 and 28,
for low-, medium-, and high-transmission areas. Although the
observed failure rates were higher in the high-transmission
area (reﬂecting the current use of ineffective drugs), the marked
differences between day 14 and 28 rates remain. A 100% treat-
ment success rate assessed at day 14 was associated with a true
failure rate of up to 46% in these studies. Figure 4 plots the
failure rate assessed at day 14 against the failure rate at max-
imum follow-up (assessed at 63 days for 17 trial arms, at 42
days for 15 trial arms, and at 28 days for 36 trial arms). As
explained above, for those trials with a maximum follow-up of
28 days the discrepancy between the failure rate estimated at
14 days and estimated true failure rate is underestimated.
Cumulative estimates of therapeutic failure and time. Fig-
ure 5 shows the relationship between the cumulative propor-
tion of failures observed and the duration of follow-up for each
of three treatment groups (short, medium, and long terminal
elimination half-lives of antimalarial drugs, respectively). The
relationships are sigmoid. There was a decrease in the slope of
the linear portion of the sigmoid curve with an increase in the
antimalarial drug half-life, although there was little difference
between the curves for drugs with short or medium half-lives.
The ﬁtted relationships reach estimated maximum sensitivities
FIG. 2. Underestimation of the true treatment failure rate. Box
plots show the median percentage (25 to 75% interquartile range;
range) of true treatment failures not detected by day 14 (black box)
and corresponding proportions of failures not detected by day 28
(white box) for antimalarial drugs with short (A), medium (B) and long
(C) elimination half-lives. The true failure rate was considered the
PCR genotype-conﬁrmed failure rate at day 63.
TABLE 3. Categorization of antimalarial treatment groups by
antimalarial drug terminal elimination half-life
Treatment
duration
Drug
half-life Therapy
Short 0–24 h Artesunate or artemether alone or in combi-
nation with antibiotics
Quinine alone or in combination with antibi-
otics (clindamycin, rifampin, tetracycline)
Medium 1–7 days Halofantrine
Artemether-lumefantrine
Atovaquone-proguanil alone or in combina-
tion with an artemisinin derivative
Sulfadoxine-pyrimethamine alone or in com-
bination with artesunate
Long 7 days Chloroquine alone or in combination with
artesunate or quinine
Meﬂoquine alone or in combination with an
artemisinin derivative
Dihydroartemisinin-piperaquine
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long half-life antimalarial drugs, respectively.
Predicting the failure rate. There was no evident relation-
ship in these studies between the failure rate observed at day
14 and the degree of underestimation of the true failure rate.
The differences were too large and unpredictable. The discrep-
ancy was consistently high and reached 100% across the whole
range of values of the true failure rates observed. For the
failure rate at day 28, a pattern of decreased differences for
highervaluesofthetruefailureratewasobserved.Thus,where-
as the day 14 assessment could not be used to predict the true
failure rate, there was a linear relationship between the day 28
assessment and the day 63 rate in these trials (Fig. 6). Fitting
the regression line estimated this relationship as follows: true
failure rate  3.49  (1.09  failure rate at day 28).
The elimination half-life of the drug did not affect the re-
sults, nor did other trial characteristics. It should be noted that
this relationship was obtained from data only in low-transmis-
sion areas, and these results cannot be extrapolated to areas of
higher malaria transmission. Table 4 lists the predicted true
failure rates for the different day 28 failure rates based on the
above model.
The relationship between newly acquired and recrudescent
infections. The occurrence of a new patent infection during
follow-up is related to the duration of follow-up, the elimina-
tion half-life of the drug, and the drug susceptibility of the
newly acquired infection. The longer the follow-up, the more
likely it is that a new infection will occur. As failure rates rise,
an increasing proportion of recurrent parasitemias are recru-
descences (i.e., treatment failures). The following exponential
growth function was found to provide the best ﬁt for the rela-
tionship between the proportion of recurrent parasitemias
which were recrudescent infections and the true failure rate
(based on studies with PCR genotyping and 63-day follow-up):
FIG. 3. Relationship of malaria transmission intensity to underestimation of failure rate. Index plots of day 14 (F) and the corresponding day 28
failure rates (E) for the malaria transmission categories in order, from left to right, of increasing day 14 failure rates. PCR genotype-corrected re-
sults are shown. Each pair of dots corresponds to one trial arm. (A) Low transmission intensity. Estimated EIR, 
2 infectious bites/person/year. (B)
Medium transmission intensity. EIR, 2 to 10 infectious bites/person/year. (C) High transmission intensity. EIR, 10 infectious bites/person/year.
FIG. 4. The relationship between the day 14 parasitological assessment and the failure rate at the maximum period of follow-up (maximum
observed failure rate). Each circle represents a trial result in which the PCR genotype-corrected maximum failure rate was known at the end of
follow-up. Black circles (F) denote results for trial arms with 63 or 42 days of follow-up, and the hollow circles (E) correspond to arm trials with
28 days of follow-up. Note that a failure rate at day 14 cannot exceed the maximum failure rate (lower triangle). A day 14 failure rate (vertical
dotted line) of 25% has been recommended as the threshold for antimalarial drug policy change.
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0.07761x) (3)
where x is the true failure rate as a percentage and y is the
proportion (expressed as a percentage) of recurrent para-
sitemias which were recrudescences (Fig. 7).
The cumulative number of documented infections at any
time is equal to the sum of the recrudescent infections (treat-
ment failures) and new infections. The number of recrudescent
infections was independent of the transmission intensity in this
large series, although most of the data derived from low-trans-
mission settings. The number of new infections depends on the
transmission intensity. Assuming that new infections cannot
become patent within 2 weeks of starting antimalarial treat-
ment and assuming a constant level of transmission, then when
the EIR is an average value of 1 infectious bite per person per
year, it can be estimated that 13% of patients would have
acquired a new infection during the 63-day follow-up, for an
EIR of 2, 27% for an EIR of 3, 40% for an EIR of 4, 54% for
an EIR of 5, and so on. In the absence of residual suppressive
drug levels and at these relatively low levels of transmission,
most or all of these infections are expected to become patent.
But at higher levels of transmission, acquired immunity plays
an increasingly important role in contributing to self-cure, and
the number of acquired infections which would become patent
cannot be estimated so conﬁdently. Using the above calcula-
tions, we estimated the number of patients with recurrent
parasitemia (recrudescences plus new infections) for given fail-
ure rates (Table 5).
Data from trials without PCR genotyping. There were 58
trial arms without adequate genotyping data which enrolled
7,456 patients. The median (range) failure rates at day 14 were
5% (0 to 97%), and the rates at day 28 were 21% (1 to 96%).
The median (interquartile range; range) day 14/day 28 failure
rate ratio as a percentage was 23% (3 to 50%; 0 to 100%).
There were 24 trials with 42-day follow-up; the median day
14/day 42 failure rate ratio (i.e., sensitivity) was 11% (0 to 29;
0 to 61%). There were 14 trials with 63-day follow up; the
median day 14/day 63 failure rate ratio was 9% (0 to 10; 0 to
32%). The median day 28/day 42 ratio for 24 studies was 50%
(41 to 72; 24 to 100%), and the median day 28/day 63 ratio for
14 studies was 25% (15 to 58; 8 to 69%).
Data from the published literature. We identiﬁed a further
21 treatment arms comprising a total of 3,259 patients where
both day 14 and day 28 failure rates were reported (11, 12, 18,
19, 38, 40, 51, 55, 56); 9 treatment arms were with drugs in the
FIG. 5. Relationship between the proportion of antimalarial treatment failures detected and the duration of follow-up for (A) short half-life,
(B) medium half-life, and (C) long half-life antimalarial drugs. PCR genotype-corrected results are shown.
FIG. 6. Relative utility of (A) day 14 assessment and (B) day 28 assessment in predicting true failure rate. PCR genotype-corrected results are
shown.
4276 STEPNIEWSKA ET AL. ANTIMICROB.A GENTS CHEMOTHER.medium half-life category, and 12 treatment arms were with
drugs in the long half-life category. The median (range) day 28
failure rate was 25% (0 to 66%). The majority of studies with
long periods of follow-up were of long half-life drugs. The day
14 assessment detected 47% (0 to 76%) of the day 28 failures.
There were only ﬁve trials with 42 days of follow-up, and in
these the day 14 assessment detected a median of 33% (0 to
62%), and the day 28 assessment was 70% (0 to 88%) of the
overall failures. This is comparable with the results from the
studies with genotyping: for day 14 assessment, 14% (0 to 80%)
and for day 28 assessment, 82% (0 to 100%). It was also
comparable with the results from the trials without genotyping:
for day 14 assessment, 11% (0 to 61%) and day 28 assessment,
50% (24 to 100%). The median (range) proportion (as a per-
centage) of day 28 failures detected at day 14 (i.e., the day
14/day 28 ratio) was 31% (0 to 73%) for day 28 failure rates of

25% (9 studies), and 51% (10 to 76%) for day 28 failure rates
of 25% (P  0.020; Mann-Whitney test).
DISCUSSION
These trials, which comprised approximately 23% of all pa-
tients enrolled in randomized trials of the drug treatment of
falciparum malaria in the past 40 years, conﬁrm that a fol-
low-up period of 14 days is insufﬁcient to characterize the
therapeutic response to antimalarial treatment. The day 14
assessment commonly missed all treatment failures. The de-
gree of underestimation was so large and so variable that it was
effectively useless as a predictor of the true failure rate, irre-
spective of the transmission setting. The day 14 assessment was
introduced by the WHO for use in settings of intense levels of
disease transmission (72) because of the operational difﬁculties
in conducting longer follow-up in trials and problems distin-
guishing recrudescences from reinfections, and because it was
considered that clinical response should be the main criterion
upon which national malaria treatment policy was based. Re-
cently, a WHO consultation group produced a review of the
methods for monitoring antimalarial resistance (73), which
emphasizes the distinction between the methods of assessment
in areas of high malaria transmission and those where trans-
mission is at a low or moderate level, and it puts more weight
than previously on parasitological measures. As before, the
“primary intent of the recommended protocol(s) is the moni-
toring of drug efﬁcacy over time for strictly programmatic pur-
poses” (73). The aim is to ensure a “minimal evidence base
from which Ministries of Health can develop informed treat-
ment guidelines and policies” (73). The meaning of these terms
is unclear. The clinical trial data presented here, derived from
a very large number of controlled trials, indicate that if the day
14 assessment is used this evidence base cannot include a true
assessment, or even an approximation, of the treatment failure
rate. A test with diagnostic sensitivity of between 0 and 37%
should never be used. Only when an antimalarial drug is failing
so badly that a signiﬁcant proportion of all infections do not
clear the parasitemia at all (e.g., R2 or R3 early treatment
failures), does the day 14 failure rate approximate the true
failure rate. At this stage mortality is rising, and it is well past
the time when the drug should be replaced. This is reﬂected in
previously published trials by the signiﬁcantly higher propor-
tion of failures detected by the 14-day assessment when the day
28 failure rate exceeded 25% (51 versus 31% of the failures
detected by day 28).
The WHO has recommended that antimalarial treatment pol-
icy should be changed when the day 14 failure rate exceeds 25%.
For Africa, four “policy states,” deﬁned by the day 14 failure rate,
FIG. 7. Relationship between the proportion of recurrent infec-
tions during a 63-day follow-up period which are true recrudescences
and the overall true failure rate in low-transmission settings. PCR
genotype-corrected data are shown.
TABLE 4. Estimated true failure rate from trial arms with
PCR genotyping and 63-day follow-up (n  17)
a
Day 28 failure
rate (%)
Predicted true
failure rate
(%)
2............................................................................................. 5
5............................................................................................. 8
10............................................................................................. 14
15............................................................................................. 19
20............................................................................................. 25
25............................................................................................. 30
30............................................................................................. 36
40............................................................................................. 47
50............................................................................................. 57
a Predicted true failure rate  y; observed failure rate at day 28  x. The true
failure rate was calculated as follows: y  3.49  1.09x.
TABLE 5. Estimated percentages of patients with reappearance
of parasites (recrudescence or new infection) by day 63
a
EIR Treatment failure
rate (%)
% of patients with
parasites by day 63
0.5 5 11
10 16
20 25
30 35
15 1 8
10 22
20 31
30 39
25 3 0
10 34
20 41
30 49
a Percentages are based on the assumption that no suppression of newly
acquired infections has occurred.
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(15 to 24%), and Change (25%). But a day 14 failure rate of
25% is compatible with a true failure rate of over 60% (Fig. 4).
This is surely unacceptable. By the time day 14 failure rates
exceed 25%, a signiﬁcant proportion of infections have early,
potentially lethal, treatment failures. A 100% success rate as-
sessed at day 14 was associated with a true failure rate, based on
parasite genotyping and 63-day follow-up, as high as 46%. These
very large differences contribute to the current widespread con-
fusion over treatment efﬁcacy with researchers pointing to in vivo
and in vitro evidence for high-level resistance, and donors and
policy makers claiming that drugs such as chloroquine and sulfa-
doxine-pyrimethamine still “work well” based on 14 day tests—
despite rising mortality (20, 25, 59). The day 28 assessment was
much better than the day 14 assessment and allowed prediction of
the true failure rate in low-transmission settings. Incorporation of
epidemiological information (an estimate of EIR) allowed pre-
diction of the true failure rates even if parasite genotyping (to
distinguish reinfection from recrudescence) was not available. As
there are no data with follow-up longer than 28 days in higher
transmission settings, we cannot estimate the degree to which the
28-day assessment underestimates the treatment failure rate in
such areas. Immunity certainly contributes to the therapeutic re-
sponse. There has been a tendency to assume that the contribu-
tion of immunity to antimalarial drug efﬁcacy malaria is uniform
across patients of a particular age, but this is unlikely to be true.
Severe malaria represents an unusual response to an unfamiliar
parasite (68). This is why there may be high rates of dangerous
early failures in antimalarial drug trials from high-transmission
settings with overall failure rates which are deemed satisfactory
(40).
Modeling the data from these trials suggested that a 42-day
follow-up captures nearly all treatment failures after treatment
with antimalarial drugs which have terminal elimination half-
lives of less than 1 week. The increased immunity in high-
transmission areas may well prevent late recrudescences, but
clearly more information on these relationships in higher-
transmission settings is needed. These data indicate clearly
that the day 14 assessment is useful only in identifying treat-
ments which should already have been replaced. It should no
longer be used. The traditional day 28 assessment is clearly
much better and does provide useful information, although it
still underestimates the true failure rate by as much as 40%.
Underestimation is greater when failure rates are low or when
slowly eliminated antimalarials are used.
The main determinants of the interval to recrudescence are the
susceptibility of the infecting parasite population, the number of
parasites present when antimalarial treatment starts, and the
pharmacokinetic properties of the antimalarial drug in the treated
patient (69). Immunity is also a factor (10, 26, 74). The distribu-
tion and range of intervals are determined by these variables. At
low levels of resistance parasite densities fall below the level of
detection in the blood, and the patient improves clinically. But the
infection is not eradicated from the body in all patients, and when
drug levels have fallen below the MIC of the drug for the infecting
parasite population, the infection reexpands (67). Following a
7-day course of a rapidly eliminated drug such as quinine or an
artemisinin derivative, the time to recrudescence averages 3
weeks and results from efﬁcient parasite multiplication after the
fourth drug exposed cycle (i.e., after 8 days) (50, 69). In the
presence of residual, partially effective concentrations of a slowly
eliminated antimalarial, the rate of parasite population reexpan-
sion is reduced, and the interval to recrudescence is often longer
than 4 weeks (52). Recrudescence is associated usually with a
return of illness, failure to recover from or worsening of anemia,
increased gametocyte carriage (and thus transmissibility) that fu-
els resistance, and a higher risk of failure with subsequent treat-
ment (45–47). Even in high-transmission settings where reinfec-
tion is inevitable within a short time, therapeutic failure is
associated with increased anemia, a major cause of childhood
death, and eventually, as resistance worsens, directly increased
mortality (37). Thus, recrudescence is associated with signiﬁcant
adverse effects both for the individual and the community. The
objective of treatment must be to cure the infection.
These data provide information which will help with the
design of antimalarial drug trials. It is evident from the results
shown in Fig. 5 that the more slowly eliminated the antimalar-
ial drug is, the longer the suppression of the eventual recru-
descence will be. For relatively sensitive infections treated with
slowly eliminated compounds, a signiﬁcant proportion of re-
crudescences occur after 42 days, and this is probably the
minimum duration of follow-up acceptable for assessing such
treatments accurately. Follow-up for more than 8 weeks is
better if possible, but there is a risk of signiﬁcant numbers of
drop-outs and reduced precision in the failure rate esti-
mates. By contrast, follow-up for 28 days captures the ma-
jority of failures with drugs such as quinine, artemisinin
derivatives, lumefantrine, atovaquone, halofantrine, and sulfa-
doxine-pyrimethamine. A 42-day follow-up is optimal for these
drugs.
The current approach to monitoring antimalarial drug resis-
tance relies upon having multiple sentinel sites which conduct
in vivo and, in some cases, in vitro monitoring. The aim is to
provide an early warning system so Ministries of Health can
respond to increasing drug resistance in a timely fashion. This
aim is undermined considerably by the common use of 14-day
assessments, because such assessments detect only very high
levels of resistance, and thus the health consequences of wors-
ening antimalarial resistance are considerably underestimated.
Furthermore, as policy change is commonly very slow to re-
spond to such information and because once the decision is
made full implementation of a malaria treatment policy usually
takes at least 18 to 24 months (3), the situation has often
deteriorated further before more-effective treatment is substi-
tuted. Several things have changed for the better in recent
years (39); there is more interest in and more ﬁnancial support
for provision of effective antimalarial drugs, the deleterious
effects of resistance on individual and public health are better
appreciated, parasite genotyping provides distinction of recru-
descence from reinfection allowing the conduct of community-
based trials, and there are better molecular markers of anti-
malarial drug resistance (4, 8, 9, 13, 46, 65). For antifol,
chloroquine, atovaquone, and meﬂoquine resistance, the mo-
lecular markers are now good enough to be used to predict
likely therapeutic responses, and the markers can be calibrated
and their predictive values further reﬁned against clinical trial
results with adequate periods of follow-up. These require only
a small blood sample to be taken and dried on ﬁlter paper. A
revision of the surveillance approach is needed. Doing fewer
trials, but doing them properly, combined with more wide-
4278 STEPNIEWSKA ET AL. ANTIMICROB.A GENTS CHEMOTHER.spread application of molecular markers (8) could well provide
a more sensitive, and thus more effective, early-warning system
that is less expensive and more informative.
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